TCT 2017: Magmaris Resorbable Magnesium Scaffold (RMS) Continues to Show No Instances of Scaffold Thrombosis
Data presented during the TCT congress on BIOTRONIK’s Magmaris1 RMS provide further evidence on its continued safety and…
Data presented during the TCT congress on BIOTRONIK’s Magmaris1 RMS provide further evidence on its continued safety and…
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce…
Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause mortality and hospitali…
Cardiology experts will present conclusive results from various BIOTRONIK studies at the European Society of Cardiology’…
BIOTRONIK’s highest performing cardiac resynchronization therapy defibrillator (CRT-D) is now available in Japan. With s…
BIOTRONIK has announced the launch of its Evity cardiac resynchronization therapy pacemaker (CRT-P) in the Japanese mark…
BIOTRONIK Studies Highlight Pertinent Questions: Can We Avoid ICD Therapy? Do CRT Patients Benefit from Rate-Adaptive Pa…
BIOTRONIK’s Magmaris resorbable scaffold offers a reduced risk of thrombus formation compared to a polymeric scaffold*.…
Results now published in the European Heart Journal show BIOTRONIK Home Monitoring® reduces the risk of all-cause mortal…
BIOTRONIK’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the…